|
May 25, 2012
|
| 06:35 EDT |  | DNDN |
| theflyonthewall.com: | Physician sentiment on Provenge remains lukewarm, says Jefferies | | After attending the American Urology Association meeting, Jefferies says physician sentiment towards Dendreon's prostate cancer drug Provenge remains lukewarm. The firm continues to believe Provenge will not obtain a firm market share before competition comes in and keeps an Underperform rating on Dendreon shares. :theflyonthewall.com |
|
|
May 23, 2012
|
| 10:27 EDT |  | DNDN |
|
|
May 22, 2012
|
| 16:08 EDT | | DNDN |
|
|
May 21, 2012
|
| 14:13 EDT |  | DNDN |
| theflyonthewall.com: | Dendreon has a conference call hosted by JP Morgan | | JP Morgan Analyst Meacham will host a conference call with CEO John Johnson on May 23 at 1 pm. :theflyonthewall.com |
|
| 10:33 EDT |  | DNDN |
|
|
May 18, 2012
|
| 10:27 EDT | | DNDN |
| theflyonthewall.com: | On The Fly: Analyst Initiation Summary | | Today's noteworthy initiations include: Acorda Therapeutics (ACOR) initiated with a Sell at Goldman... Bristol-Myers (BMY) initiated with an Outperform at BMO Capital... Corning (GLW) initiated with a Neutral at Susquehanna... Cree (CREE) initiated with a Positive at Susquehanna... Exactech (EXAC) initiated with a Buy at Benchmark Co... Hawaiian Holdings (HA) initiated with an Outperform at Imperial Capital... Mattel (MAT) initiated with a Buy at SunTrust... Merck (MRK) initiated with a Market Perform at BMO Capital... Micron (MU) initiated with a Buy at ThinkEquity... SanDisk (SNDK) initiated with a Hold at ThinkEquity... Spansion (CODE) initiated with a Buy at ThinkEquity... Dendreon (DNDN) initiated with a Sell at Maxim. :theflyonthewall.com |
|
| 09:19 EDT | | DNDN |
| theflyonthewall.com: | Deutsche Bank's biotech analyst to hold a conference call | | Biotech Analyst Karnauskas discusses Dendreon's Provenge on an Analyst/Industry conference call to be held on May 18 at 2 pm. :theflyonthewall.com |
|
| 07:57 EDT | | DNDN |
| theflyonthewall.com: | Dendreon initiated with a Sell at Maxim | | Maxim believes Dendreon's prostate cancer drug Provenge will have a difficult time growing market share given its complexity and manufacturing obstacles. The firm initiated Dendreon shares with a Sell rating and $5 price target. :theflyonthewall.com |
|
|
May 17, 2012
|
| 10:36 EDT | | DNDN |
|
| 10:23 EDT | | DNDN |
| theflyonthewall.com: | Dendreon weakness overdone, says Deutsche Bank | | Deutsche Bank said the SEC investigation into Dendreon is old news and was posted on May 7 in the 10-Q. The firm believes weakness is overdone and reiterates its Buy rating. :theflyonthewall.com |
|
| 10:00 EDT |  | DNDN |
| theflyonthewall.com: | Dendreon falls 12.7% | | Dendreon is down 12.7%, or $1.09, to $7.52 :theflyonthewall.com |
|
| 09:02 EDT | | DNDN |
|
|
May 16, 2012
|
| 17:12 EDT | | DNDN |
| theflyonthewall.com: | SEC opens probe into Dendreon, possible regarding Provenge disclosures | | This is being reported by Dow Jones. :theflyonthewall.com |
|
|
May 15, 2012
|
| 12:49 EDT | | DNDN |
|
Subscribe for More Information